Frias JP, Bastyr EJ 3rd, Vignati L et al (2017) The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Inject once weekly as directed by your healthcare provider using a vial and syringe
For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM, that explain poor responders to their medications. For now, the mechanism driving GLP-1 resistance remains unresolved, but it is likely complex and multifactorial, Gloyn said
The Cavitation treatment does not require any special pre-treatment or preparation
The first reconstitution and the first injection are taught in person, not over video